bioAffinity to sponsor CHEST 2026 Learning Theater on CyPath Lung and asthma/COPD research

bioAffinity Technologies, Inc.

bioAffinity Technologies (Nasdaq: BIAF, BIAFW) will sponsor a Learning Theater at CHEST 2026 on Oct. 21, 2026, 12:30-1:15 p.m. MST in Phoenix.
Chief Medical Officer Gordon H. Downie, MD, PhD, will present on CyPath Lung for lung cancer risk stratification and pulmonary nodule management.
CyPath Lung clinical trial data: 92% sensitivity, 87% specificity, 88% accuracy, 99% negative predictive value for small indeterminate nodules under 20 mm.
Presentation will discuss preliminary data from an investigational asthma/COPD lung inflammation test.
Medical and Scientific Advisory Board to meet; members include David Hill, David Ost, Daniel Sterman, Sheila Habib, J. Scott Ferguson, Neil Alexis and Sandeep Bansal.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.